Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - krizotiniib - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.

Euroopa Liit - eesti - EMA (European Medicines Agency)

roche registration gmbh - alekintiibvesinikkloriid - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - alecensa nagu monotherapy on näidustatud esimese rea raviks täiskasvanud patsientidel, kellel anaplastic lümfoom kinase (kristallimise)-positiivne kaugelearenenud mitteväikerakk-kopsuvähk (mitteväikerakk-kopsuvähi). alecensa nagu monotherapy on näidustatud ravi täiskasvanud patsientidel, kellel kristallimise‑positiivne kaugelearenenud mitteväikerakk-kopsuvähi varem ravitud crizotinib.

Euroopa Liit - eesti - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - kartsinoom, mitteväikerakk-kopsu - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - erlotiniib - õhukese polümeerikattega tablett - 150mg 30tk

Eesti - eesti - Ravimiamet

actavis group ptc ehf. - erlotiniib - õhukese polümeerikattega tablett - 150mg 30tk

Eesti - eesti - Ravimiamet

teva b.v. - erlotiniib - õhukese polümeerikattega tablett - 150mg 1tk 30tk

Eesti - eesti - Ravimiamet

teva pharma b.v. - erlotiniib - õhukese polümeerikattega tablett - 150mg 1tk 30tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - erlotiniib - õhukese polümeerikattega tablett - 25mg 30tk

Eesti - eesti - Ravimiamet

teva b.v. - erlotiniib - õhukese polümeerikattega tablett - 100mg 1tk 30tk